Quest Diagnostics gains NYSDOH approval for Haystack MRD, expanding the cancer test to all 50 states and strengthening its oncology reach.
Add Yahoo as a preferred source to see more of our stories on Google. Haystack Oncology focuses on advancing liquid biopsy technologies. Credit: Gorodenkoff ...
Fourteen City of Hope sites across the U.S. participating in research using the Haystack MRD ctDNA Test in patients with breast, colorectal, ovarian, and prostate cancer SECAUCUS, N.J. and LOS ANGELES ...
Quest Diagnostics® (NYSE: DGX), a leading provider of diagnostic information services, today announced that the New York State Department of Health's (NYSDOH) Clinical Laboratory Evaluation Program ...
Quest is the largest reference laboratory to embed oncology molecular ordering into OncoEMR MPI, with projected reach to 4,700 clinicians across ~1,600 community oncology sites. Integration targets ...
Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced it is integrating its ...
Quest Diagnostics has received approval from the New York State Department of Health's (NYSDOH) Clinical Laboratory Evaluation Programme for its Haystack minimal residual disease (MRD) test, expanding ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results